Search Results

Scientists from global biopharmaceutical company MSD will come to the Crick next year to tackle a range of conditions associated with ageing such as dementia and Parkinson’s disease.

Artios Pharma Limited, a biotech company established with the help and expertise of Francis Crick Institute scientist Simon Boulton, has secured an additional $86m (£65m) to advance its first-in-class small molecule DNA repair programmes into the clinic.